Infinity Pharmaceuticals | INFI - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
AbbVie USD 5.81B 1.23B 2025-12
Alterity Therapeutics Limited AUD -7.77M 2.99M 2023-06
Amgen USD 3.96B 464M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Cipla INR 9.77B 6.21B 2025-12
Clal Biotechnology ILS -1.74M 7.46M 2022-12
Compugen USD 56.04M 63.93M 2025-12
CSL USD 2.64B 1.97B 2025-12
Eisai JPY 20.03B 6.36B 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Grifols EUR 320.55M 91.01M 2025-12
Incyte USD 383.88M 47.43M 2025-12
Infinity Pharmaceuticals USD -10.12M 1.39M 2023-06
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
J&J USD 5.59B 1.81B 2025-12
Novartis USD 4.06B 437M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
TG Therapeutics USD 50.49M 21.13M 2025-12